Severe Acute Respiratory Syndrome Coronavirus 2 Clinical Trial
Official title:
Host-pathogen Interactions During Paediatric and Adult SARS-CoV-2 Infection (COVID-19)
The new Severe acute respiratory syndrome coronavirus (SARS-CoV-2) named coronavirus disease 2019 (COVID-19) is currently responsible for a pandemic spread of febrile respiratory infections, responsible for a veritable global health crisis. In adults, several evolutionary patterns are observed: i) a/pauci-symptomatic forms; ii) severe forms immediately linked to rare extensive viral pneumonia; and iii) forms of moderate severity, some of which progress to secondary aggravation (Day 7-Day 10). Children can be affected, but are more rarely symptomatic and severe pediatric forms are exceptional. Like some other coronaviruses (SARS-CoV and Middle East respiratory syndrome coronavirus (MERS-CoV)), these differences in clinical expression could be based on a variability in the immunological response, notably either via inhibition of the type I interferon (IFN-I) response, or on the contrary an immunological dysregulation responsible for a "cytokine storm" associated with the aggravation. Little is known about the impact of these innate immune response abnormalities on the adaptive response. In addition, certain genetic factors predisposing to a state of "hyper-fragility" and certain viral virulence factors could also be predictive of the clinical response. In this context, the main hypothesis is that the virological analysis and the initial biological and immunological profiles are correlated with the initial clinical presentation of COVID-19 infection. In particular, children forms and pauci-symptomatic disease in adults may be linked to a more robust innate immune response, including better production of IFN-I.
n/a
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Recruiting |
NCT05543616 -
A Study to Learn About Variant-Adapted COVID-19 RNA Vaccine Candidate(s) in Healthy Children
|
Phase 2/Phase 3 | |
| Recruiting |
NCT04516811 -
Therapeutic Use of Convalescent Plasma in the Treatment of Patients With Moderate to Severe COVID-19
|
Phase 3 | |
| Completed |
NCT04334044 -
Treatment of SARS Caused by COVID-19 With Ruxolitinib
|
Phase 1/Phase 2 | |
| Terminated |
NCT04371978 -
Efficacy and Safety of Dipeptidyl Peptidase-4 Inhibitors in Diabetic Patients With Established COVID-19
|
Phase 3 | |
| Recruiting |
NCT04466241 -
Combination Therapies to Reduce Carriage of SARS-Cov-2 and Improve Outcome of COVID-19 in Ivory Coast: a Phase Randomized IIb Trial
|
Phase 2/Phase 3 | |
| Withdrawn |
NCT04381923 -
COVIDNOCHE Trial (HFNO Versus CPAP Helmet) in COVID-19 Pneumonia
|
N/A | |
| Recruiting |
NCT04402879 -
CORONA (COvid pRONe hypoxemiA): Prone Positioning for Hypoxemic COVID-19 Patients With Do-not-intubate Goals
|
N/A | |
| Recruiting |
NCT04661631 -
Surgery and Lung Ultrasound in COVID-19 Infection
|
||
| Completed |
NCT04375098 -
Efficacy and Safety of Early COVID-19 Convalescent Plasma in Patients Admitted for COVID-19 Infection
|
Phase 2 | |
| Completed |
NCT04402060 -
A Study of APL-9 in Adults With Mild to Moderate ARDS Due to COVID-19
|
Phase 1/Phase 2 | |
| Active, not recruiting |
NCT04365101 -
Natural Killer Cell (CYNK-001) Infusions in Adults With COVID-19
|
Phase 1/Phase 2 | |
| Completed |
NCT04354779 -
Antibody Seroprevalence and Rate of Asymptomatic Infections With SARS-CoV-2 in Austrian Hospital Personnel.
|
||
| Recruiting |
NCT04367207 -
African Covid-19 Critical Care Outcomes Study
|
||
| Terminated |
NCT04409873 -
Antiseptic Mouthwash / Pre-Procedural Rinse on SARS-CoV-2 Load (COVID-19)
|
Phase 2 | |
| Completed |
NCT04602351 -
Communication in ICU During COVID-19
|
||
| Terminated |
NCT04707703 -
Isavuconazole for the Prevention of COVID-19-associated Pulmonary Aspergillosis
|
Phase 3 | |
| Active, not recruiting |
NCT04987528 -
Pulmonary Fibrosis During Severe COVID-19 Pneumonia
|
||
| Completed |
NCT04667936 -
Evaluation of Sedation in COVID-19 ARDS
|
||
| Completed |
NCT04423770 -
COVID-19 Related Health and Infection Control Practices Among Dentists
|
||
| Completed |
NCT04379037 -
Vagus Nerve Stimulation ARDS Prevention Trial for COVID-19 Hospitalized Patients
|
N/A |